A Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer



Status:Recruiting
Conditions:Cancer, Cancer, Pancreatic Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:11/23/2018
Start Date:March 27, 2018
End Date:December 31, 2019
Contact:Maria Loushin
Email:Maria.Loushin@TymeInc.com
Phone:212-461-2198

Use our guide to learn which trials are right for you!

A Phase II Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred After/on First Line Chemotherapy

A prospective, open-label phase 2 trial in metastatic pancreatic cancer subjects who have
failed at least one line of any prior chemotherapy. The trial is designed to evaluate the of
SM-88 therapy on pancreatic cancer and will measure multiple efficacy and safety endpoints,
including overall response rate, overall survival, progression free survival, relevant
biomarkers, quality of life and safety. In the initial stage of the trial (36 subjects), two
dose levels of SM-88's metyrosine-derivative will be evaluated.

Both investigator determined and independent blinded central review will be used for
determining outcomes.

Inclusion Criteria:

1. Biopsy-proven metastatic pancreatic adenocarcinoma with documented radiographic
disease progression on or after one or more systemic therapies. Chemotherapy given as
part of prior chemoradiation in the setting of non-metastatic pancreatic cancer does
not count as a line of therapy. Chemotherapy given for at least 4 months as adjuvant
after complete response is considered as a first line therapy.

2. Subjects must be unwilling or unable to tolerate other non-study systemic
chemotherapy.

3. Subjects must have measurable lesions (according to standard RECIST 1.1).

4. Subjects must have completed systemic therapy at least 28 days prior to first dose.

5. Subjects must have recovered from major side effects of prior therapies or procedures.

6. ≥18 years of age.

7. ECOG performance status ≤2.

8. Life expectancy >3 months, in the judgment of the investigator.

9. Adequate organ function defined as follows:

1. Hematologic: Platelets ≥100 x 10(9)/L; ANC ≥1.5 x 10(9)/L (without platelet
transfusion or growth factors within the 7 days prior to the screening laboratory
assessment)

2. Hepatic: aspartate transaminase (AST)/alanine transaminase (ALT) ≤2.5 x upper
limit of normal (ULN); total or conjugated bilirubin ≤1.5 x ULN

3. Renal: serum creatinine ≤1.5 x ULN or creatinine clearance (CrCl) ≥60 mL/min as
calculated by the Cockroft-Gault method

10. Coagulation: International normalized ratio (INR) ≤1.2 within 28 days of starting
study.

11. All acute toxic effects of any prior antitumor therapy resolved to Grade ≤1 before
baseline, with the exception of alopecia and neurotoxicity (CTCAE Grade 1 or 2
permitted).

12. Able and willing to provide written informed consent to participate in this study.

13. Subject is willing and able to comply with the protocol for the duration of the study
including undergoing treatment and scheduled visits and examinations including follow
up.

14. Subjects must be able to swallow whole capsule.

15. Female subjects must either be of non-reproductive potential, not breast-feeding or
must have a negative urine or serum pregnancy test within 28 days of study treatment,
confirmed prior to treatment on day 1.

16. Subjects of fertile potential who engage in heterosexual intercourse with partners of
childbearing potential must agree to use highly effective contraception while enrolled
in the study and for at least 6 months following the last dose of study drug

Exclusion Criteria:

1. Any screening laboratory, electrocardiogram (ECG), or other findings that, in the
opinion of the investigator or the sponsor, indicate an unacceptable risk for the
subject's participation in the study.

2. History or evidence of any clinically significant disorder, condition, or disease
that, in the opinion of the investigator or medical monitor would pose a risk to the
subject's safety or interfere with the study evaluations, procedures, or completion.
Examples include intercurrent illness such as active uncontrolled infection, active or
chronic bleeding event within 28 days of baseline, uncontrolled cardiac arrhythmia, or
psychiatric illness/social situation that would limit compliance with study
requirements.

3. History of a concurrent or second malignancy, except for adequately treated local
basal cell or squamous cell carcinoma of the skin, adequately treated superficial
bladder cancer, adequately treated Stage 1 or 2 cancer currently in complete
remission; or any other cancer that has been in complete remission for ≥5 years.

4. Subjects with MSI-H pancreatic cancer who have not previously received pembrolizumab.

5. Radiation to all target lesions within 12 weeks of study baseline,

6. No measurable target lesions.

7. Current use, or up to 14 days prior use, of certain prohibited medication or requires
any of these medications during treatment phase.

8. Major surgery, defined as any surgical procedure that involves general anesthesia and
a significant incision (i.e. larger than that required for placement of central venous
access, percutaneous feeding tube, or biopsy) within 28 days of the first dose of
study drug

9. Minor surgical procedures within 7 days of baseline, or not yet recovered from prior
surgery.

10. Any dysphagia, odynophagia, esophageal dysmotility or stricture, known GI
malabsorption syndrome, or intractable diarrhea that may significantly alter the
absorption of any of the components of SM-88, e.g., cirrhosis.

11. Known human immunodeficiency (HIV) virus infection.

12. Known hepatitis B surface antigen (HBsAg) positive.

13. Known hepatitis C virus (HCV) antibody positive.

14. Have previously been enrolled in this study or any other study investigating SM-88 or
who have previously received any component of SM-88 in a clinical trial.

15. History of any drug allergies or significant adverse reactions to any of the
components of SM-88.

16. Are currently enrolled in, or have discontinued within 30 days of screening, from a
clinical trial involving an investigational product or non-approved use of a drug or
device.

17. Subjects must not have any clinically significant and uncontrolled major medical
condition(s) including, but not limited to uncontrolled nausea/vomiting/diarrhea;
active uncontrolled infection; symptomatic congestive heart failure (New York Heart
Association [NYHA] class >= II); unstable angina pectoris or cardiac arrhythmia;
psychiatric illness/social situation that would limit compliance with study
requirements.

18. >10% weight loss over the 28 days prior to consent.

19. Subject has a variety of factors influencing oral drugs (such as unable to swallow,
nausea, vomiting, chronic diarrhea and intestinal obstruction, etc.).

20. Subjects with central nervous system metastasis; with the exception of subjects who
have stable brain metastases as defined as off steroids and no CNS progress for 6
months after CNS treatment.

21. Pregnant or lactating women.

22. History of psychiatric drug abuse that cannot be ended, or subjects with mental
disorders that will prevent compliance or evaluation including uncontrolled
schizophrenia, uncontrolled depression or other uncontrolled disorders.

23. Subjects with a history of hypersensitivity to phenytoin, its inactive ingredients, or
other hydantoins; or a history of prior acute hepatotoxicity attributable to
phenytoin.

24. Subjects exhibiting idiosyncratic reactions to psoralen compounds.

25. Subjects with a hypersensitivity to sirolimus.

26. Subjects with a history of the light sensitive diseases for which methoxsalen would be
contraindicated. Diseases associated with photosensitivity include lupus
erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate
porphyria, xeroderma pigmentosum, and albinism.

27. Subjects treated, or anticipated to be treated, with delavirdine (due to potential for
loss of virologic response and possible resistance to delavirdine or to the class of
non-nucleoside reverse transcriptase inhibitors caused by phenytoin).

28. Subjects with melanoma or with a history of melanoma, invasive squamous cell
carcinomas, or aphakia (due to contraindication for use of methoxsalen).

29. Subjects with prior organ transplant or being treated, or anticipated to be treated,
with cyclosporine (because long-term administration of the combination of cyclosporine
and sirolimus is associated with deterioration of renal function).

30. Subjects with a seizure disorder that is not well controlled or who have required a
change in seizure medications within 60 days of enrollment to the trial.

31. Subjects treated, or anticipated to be treated, with a calcineurin inhibitor (because
concomitant use of sirolimus and a calcineurin inhibitor increases the risk of
calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic
purpura/thrombotic microangiopathy [HUS/TTP/TMA]).

32. Subjects with interstitial lung disease (ILD) (including pneumonitis, bronchiolitis
obliterans organizing pneumonia [BOOP], and pulmonary fibrosis).
We found this trial at
29
sites
Santa Monica, California 90404
Principal Investigator: Lee Rosen, MD
Phone: 310-633-8400
?
mi
from
Santa Monica, CA
Click here to add this to my saved trials
1211 Medical Center Dr
Nashville, Tennessee 37232
(615) 322-5000
Principal Investigator: Dana Cardin, MD
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
12902 USF Magnolia Dr
Tampa, Florida 33612
(888) 663-3488
Principal Investigator: Dae Won Kim, MD
Phone: 813-745-6454
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Albany, New York 12206
Principal Investigator: Lawrence Garbo, MD
Phone: 518-489-0044
?
mi
from
Albany, NY
Click here to add this to my saved trials
Arlington Heights, Illinois 60005
Principal Investigator: Richard Siegel, MD
Phone: 847-259-4482
?
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
Billings, Montana 59102
Principal Investigator: Patrick Cobb, MD
Phone: 406-238-6962
?
mi
from
Billings, MT
Click here to add this to my saved trials
Bronx, New York 10469
Principal Investigator: Harry Staszewski, MD
Phone: 631-675-5143
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Cincinnati, Ohio 45226
Principal Investigator: Mark E Johns, MD
Phone: 888-961-4131
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
281 W. Lane Ave
Columbus, Ohio 43210
(614) 292-6446
Principal Investigator: Anne Noonan, MD
Phone: 614-293-4822
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Dallas, Texas 75246
Principal Investigator: KRISTI MCINTYRE, MD
Phone: 214-739-4175
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Dallas, Texas 75246
Principal Investigator: Carlos Becerra, MD
Phone: 214-370-1000
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Detroit, Michigan 48201
Principal Investigator: Philip Philip, MD
Phone: 313-576-9385
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Duarte, California 91010
Principal Investigator: Vincent Chung, MD
Phone: 626-359-8111
?
mi
from
Duarte, CA
Click here to add this to my saved trials
East Setauket, New York 11733
Principal Investigator: Harry Staszewski, MD
Phone: 631-675-5143
?
mi
from
East Setauket, NY
Click here to add this to my saved trials
East Setauket, New York 11733
Principal Investigator: Harry Staszewski, MD
?
mi
from
East Setauket, NY
Click here to add this to my saved trials
8503 Arlington Blvd., Ste. 400
Fairfax, Virginia 22031
(703) 280-5390
Principal Investigator: Raymond Wadlow, MD
Phone: 703-280-5390
Virginia Cancer Specialists, PC Now the world's most advanced cancer treatment capabilities can be found...
?
mi
from
Fairfax, VA
Click here to add this to my saved trials
Fayetteville, Arkansas 72703
Principal Investigator: J. Thaddeus Beck, MD
Phone: 479-587-1700
?
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Fort Worth, Texas 76104
Principal Investigator: Henry Xiong, MD
Phone: 817-759-7023
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Mesa, Arizona 85206
Principal Investigator: Kasra Karamlou, MD
Phone: 480-854-1130
?
mi
from
Mesa, AZ
Click here to add this to my saved trials
New Orleans, Louisiana 70112
Principal Investigator: Jyotsna Fuloria, MD
Phone: 504-702-5700
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
New York, New York 10028
Principal Investigator: Harry Staszewski, MD
Phone: 631-675-5143
?
mi
from
New York, NY
Click here to add this to my saved trials
Papillion, Nebraska 68046
Principal Investigator: Timothy Huyck, MD
?
mi
from
Papillion, NE
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Andrea Wang Gillam, MD
Phone: 314-362-5740
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Santa Monica, California 90403
Principal Investigator: Steve Wong, MD
Phone: 310-552-9999
?
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Seattle, Washington 98101
(888) 862-2737
Principal Investigator: Vincent Picozzi, MD
Phone: 206-287-5671
Virginia Mason Medical Center Established in 1920, Virginia Mason began as an 80-bed hospital with...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Sioux City, Iowa 51101
Principal Investigator: Donald Wender, MD
?
mi
from
Sioux City, IA
Click here to add this to my saved trials
Southington, Connecticut 06489
Principal Investigator: Peter Byeff, MD
Phone: 860-244-4408
?
mi
from
Southington, CT
Click here to add this to my saved trials
Tampa, Florida 33613
Principal Investigator: Alexander Rosemurgy, MD
Phone: 813-615-7068
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Tyler, Texas 75702
Principal Investigator: Donald Richards, MD
Phone: 903-579-9800
?
mi
from
Tyler, TX
Click here to add this to my saved trials